2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness

By afschroeder • August 5, 2025

Bhimraj A, Falck-Ytter Y, Baden LR, Bedimo R, Cawcutt K, Cheng VC, Chew KW, Chiotos K, Daar ES, Dzierba AL, Glidden DV, Hardy EJ, Johnson S, Kim AY, Li JZ, MacBrayne C, Martin GS, Nadig N, Nakamura MM, Pearson JC, Riley L, Shafer RW, Shoham S, Shumaker AH, Tebas P, Tien PC, Loveless J, Morgan RL, Gandhi RT. 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness. Clin Infect Dis. 2025 Aug 4:ciaf424. doi: 10.1093/cid/ciaf424. Epub ahead of print. PMID: 40757658.

Tags: abatacept, covid-19, Harbor UCLA, Infectious Diseases, infliximab, pemivibart, Publications, vilobelimab

Lessons From the Past

Budoff MJ. Lessons From the Past. J Soc Cardiovasc Angiogr Interv. 2026 Mar 12;5(4):104276. doi: 10.1016/j.jscai.2026.104276. PMID: 42111096; PMCID: PMC13154623.

Reassessing alcohol consumption and cardiovascular disease by addressing bias in observational data: results from the Multi-Ethnic Study of Atherosclerosis

Srivatsa S, Farkouh EK, Stockwell T, Pike JR, Clay JM, Bey G, Nasir K, Budoff M, Naimi T, Farkouh ME. Reassessing alcohol consumption and cardiovascular[...]

Pulmonary Rehabilitation Prolongs Life…And May Be Dying

Mosher CL, Casaburi R. Pulmonary Rehabilitation Prolongs Life…And May Be Dying. Am J Respir Crit Care Med. 2026 Apr 7:aamag168. doi: 10.1093/ajrccm/aamag168. Epub ahead of[...]